Thermal stability of rhC2 was assessed with differential scanning calorimetry using a MicroCal VP-DSC (GE Healthcare, Piscataway, NJ) with 400 l buffer (25 mM sodium phosphate, 500 mM sodium chloride) per buffer/sample pairs in 96 deep well plates loaded in the CapVP-DSC autoloader

Thermal stability of rhC2 was assessed with differential scanning calorimetry using a MicroCal VP-DSC (GE Healthcare, Piscataway, NJ) with 400 l buffer (25 mM sodium phosphate, 500 mM sodium chloride) per buffer/sample pairs in 96 deep well plates loaded in the CapVP-DSC autoloader. 95% and it was characterized for stability and activity. It was sensitive to C1s cleavage and restored classical complement pathway activity in C2-deficient serum both in a complement activation ELISA and a hemolytic assay. Furthermore, rhC2 could increase C3 fragment deposition on the human pathogenStreptococcus pneumoniaein C2-deficient serum to levels equal to those with normal serum. == Conclusions == Taken together these data suggest that recombinant human C2 can restore classical complement pathway activity and may A66 serve as a potential therapeutic for recurring bacterial infections or SLE in C2-deficient patients. == Background == Our understanding of the role of complement in human disease is the result of numerous studies in recent years focused on complement’s mechanism of action. This has resulted in achieving important information on the role of complement as a major mediator and effector mechanism in diseases of immune and non-immune pathogenesis. Complement is not only important for protection against microorganisms, but also contributes to the pathophysiology of a number of autoimmune diseases. Progress regarding the biological role of complement has been made by studying disease associations in patients with inherited complement protein deficiencies [1]. Genetic deficiencies of complement components are a common denominator of immune and infectious diseases. Deficiencies of complement components of the classical activation pathway, C1, C2 and C4, all A66 lead to increased susceptibility to A66 bacterial infections [2] and increased risk of developing autoimmune disease, particularly systemic lupus erythematosus (SLE) [3]. The complement system consists of more than 30 soluble and membrane proteins and constitutes an important mediator of host defense against foreign pathogens. Complement component C2 functions as a key regulator in the early activation phase of the classical pathway and participates in the formation of the classical pathway C3 convertase C4b2a [4]. C2 is also a critical component of the lectin pathway. Specifically, when mannose-binding lectin (MBL) or ficolins in complex with MBL-associated serine protease (MASP) molecules bind to relevant carbohydrate molecules, this leads to activation of MASP-2 which then may cleave both C2 and C4 thereby forming the same C3 convertase as in classical pathway activation [5]. Thus, C2 is an important component of both the classical and the lectin pathways of complement activation and is involved in first line defense against microbial infection that is essential for detection and clearance of the invading pathogens [6]. Complement C2 deficiency is the most common genetically determined complete complement deficiency with a prevalence estimated to be approximately 1:20,000 in individuals of Caucasian ancestry [3], making it a clinically important immune deficiency [7]. The deficiency is, in the majority of cases, caused by homozygosity for C2 genes having deletions in exon 6, resulting in complete absence of C2, or in some cases caused by other C2 gene mutations [8,9] The alternative activation pathway, which is C3 dependent, is generally intact in C2 deficiency and can trigger formation of the membrane attack complex (MAC) independently of C2 [4]. However, in the absence of C2, C3 is, in many situations, not efficiently cleaved Mouse monoclonal to CEA resulting in a limited deposition of C3 fragments on immune complexes and on the surface of apoptotic cells. Circulating apoptotic cells become a source of self antigen for auto-antibodies that participate in the formation of immune complexes. The immune complexes are deposited throughout the body, potentially leading to localized inflammatory reactions in bones and kidneys, and eventually resulting in renal disease from persistent activation from the enhance system [10]. Within this research, we regarded C2 replacement being a healing focus on to explore the feasibility of rebuilding the enhance pathway in situations of C2 insufficiency. It’s been previously suggested that purified individual C2 could restore traditional and lectin enhance pathways and hemolytic activityex-vivoin serum gathered from C2-lacking sufferers [11]. Two case histories A66 have already been defined where regular infusions of clean frozen plasma had been beneficial in sufferers with C2-insufficiency and SLE; this advantage was ascribed towards the C2 within the clean iced plasma [12,13]. For that reason, we hypothesized that recombinant individual enhance element C2 (rhC2) could restore enhance activity in serum A66 from C2-lacking patients. To check this hypothesis we’ve portrayed and purified rhC2 and evaluated enhance activationin vitro. To your knowledge.